Key result
Supervised 12-week HIIT reduces prostate cancer-specific anxiety versus usual care.
Why the study?
The study evaluated the effects of exercise on prostate cancer-specific anxiety, fear of cancer progression, quality of life, and psychosocial outcomes in prostate cancer patients undergoing active surveillance.
Does a 12-week supervised HIIT program improve prostate cancer-specific anxiety and quality of life in patients with prostate cancer on active surveillance?
RCT (n=52)
Does a 12-week supervised HIIT program improve prostate cancer-specific anxiety and quality of life in patients with prostate cancer on active surveillance?
Mean Difference: -2.7 (95% CI -5–-0.4)
p-value: p=0.024
A 12-week supervised HIIT program significantly improves prostate cancer-specific anxiety, fear of progression, and psychosocial outcomes in men on active surveillance.
Supervised HIIT reduced prostate cancer-specific anxiety and fear of progression versus usual care; supports adding exercise to active surveillance care pending confirmatory trials.
PURPOSE: We examined the effects of exercise on prostate cancer-specific anxiety, fear of cancer progression, quality of life and psychosocial outcomes in patients with prostate cancer on active surveillance. MATERIALS AND METHODS: The ERASE (Exercise during Active Surveillance for Prostate Cancer) Trial randomized 52 patients with prostate cancer undergoing active surveillance to high-intensity interval training (HIIT, 26 patients) or usual care (UC, 26 patients). The HIIT group performed a 12-week, thrice weekly, supervised, aerobic HIIT program. The UC group did not exercise. Patient-reported outcomes were assessed at baseline and after intervention, including prostate cancer-specific anxiety (Memorial Anxiety Scale for Prostate Cancer), fear of cancer progression (Fear of Cancer Recurrence Inventory), prostate cancer symptoms (Expanded Prostate Cancer Index Composite), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core) and psychological health outcomes (eg fatigue, stress and self-esteem). Analysis of covariance was used to compare between-group differences. RESULTS: Fifty of 52 participants (96%) completed patient-reported outcome assessments at 12 weeks. Adherence to HIIT was 96%. Compared to UC, HIIT significantly improved total prostate cancer-specific anxiety (adjusted between-group mean difference -2.7, 95% confidence interval, range -5.0 to -0.4, p=0.024), as well as the fear of progression subscale (p=0.013), hormonal symptoms (p=0.005), perceived stress (p=0.037), fatigue (p=0.029) and self-esteem (p=0.007). CONCLUSIONS: A 12-week supervised HIIT program may improve prostate cancer-specific anxiety, fear of cancer progression, hormone symptoms, stress, fatigue and self-esteem in men with prostate cancer on active surveillance. Larger trials are needed to confirm the effects of HIIT on patient-reported outcomes in the active surveillance setting.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted an RCT in Prostate cancer on active surveillance (n=52). High-intensity interval training (HIIT) vs. Usual care was evaluated on Total prostate cancer-specific anxiety (MD -2.7, 95% CI -5.0 to -0.4, p=0.024). A 12-week supervised HIIT program significantly improved total prostate cancer-specific anxiety compared to usual care (MD -2.7; 95% CI -5.0 to -0.4; p=0.024).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: